Wellpharma

Developed jointly by Bristol Myers Squibb and Pfizer, Eliquis continues to be a solid revenue driver. Generating $16.7 billion in total revenue, global drug sales were up 20% in 2021. In the U.S., fourth-quarter sales increased 22% versus prior year, driven primarily by total prescription growth of 13%, Bristol Myers Squibb Chief Financial Officer David Elkins said on the companys 2021 Q4 earnings call. Eliquis remains the most popular oral anticoagulant in many countries.